Skip to main content

Table 1 Expression of various markers in PTs obtained from patients or patient-derived xenografts

From: Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells

  % positive cases (n = 51) BC007/BC-P007MT1 BC107/BC-P107MT1 BC515/BC-P515MT1 BC877/BC-P877MT1 HS-5
(% positive cells)
MSC marker CD44 68.6% 50/60 60/30 -/- -/- +
CD29 27.4% 10/40 <5/30 5/<1 -/- +
CD166 78.4% <5/< 5 10/50 5/5 90/90 +
CDI06 29.4% 30/<10 <10/<10 -/- 80/80 +
CD105 1.9% -/- -/- -/- 50/90 +
CD90 78.4% <10/< 10 10/10 55/75 <5/70 +
CD117 70.5% -/20 -/- 5/50 80/95 +
GD2 100% 80/50 75/30 90/75 60/30 +
(<10 to >90)      
Stem cell marker ALDH 100% 20/1 3-5/<1 40/5 <1/<5 +
(<10 to >90)      
Oct-4 47.0% 10/5 30/10 <1/35 <5/<5 +
PT clinically relevant markers Vimentin 100% 90/ > 90 90/>70 80/20 >95/>95 +
(<10- to >90)      
Ki-67 82.3% 40/40 10/20 5/<3 65/>95 +
CD10 60.7% 20/5 10/70 5/5 <10/30 +
CD34 52.9% -/- 40/70 80/20 -/- -
p53 50.9% <10/<10 <5/10 70/60 >95/>95 +
Bcl-2 37.2% -/- -/- -/- -/- -
p63 9.8% 60/10 -/- -/- -/- -
Globo-H 9.8% -/- -/- -/- 80/80 -
  1. Fifty-one malignant PTs were tested by immunohistochemical staining for a panel of 18 markers. The expression level of each marker was scored based on the positive percentage by stained cells by clinical pathologists. The percentage of all 51 cases expressing each marker is listed in the third row. The xenografted tumors in NO-SCID mice (BC-P007MT1, BC-P107 MT1, BC-P515 MT1 and BC-P877 MT1) showed a similar immunohistochemical staining profile for most markers as did the parental tumors (BC007, BC107, BC515 and BC877). All markers were expressed in malignant PTs. HS-5 (human marrow stromal cell lines) as the control in this table, the expression level of each marker was classified into two categories, negative (-) and positive (+), by clinical pathologists.